| abstract |
Provided are novel therapeutic agents for autoimmune diseases, particularly type 1 diabetes and rheumatoid arthritis. By producing a novel anti-CD98 antibody and using it, it has become possible to provide a novel therapeutic agent with a new mechanism of action for autoimmune diseases (type 1 diabetes and rheumatoid arthritis). This novel anti-CD98 antibody does not inhibit the amino acid transport of CD98, and unlike the known anti-CD98 antibody, it further has a T lymphocyte activation inhibitory action and a fibronectin-mediated cell adhesion inhibitory action, and OVA sensitization. The model has an action such as suppressing the production of OVA antibody. |